Current Report ESPI 9/2025

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland (the “Company” or the “Issuer”), announces that on April 8, 2025, it decided not to enter into a grant agreement with the Medical Research Agency (in Polish: Agencja Badań Medycznych, “MRA”) regarding the project titled: “Identification of selection markers for patients that can benefit from the treatment with novel PRMT5 developed by Ryvu Therapeutics” (Ref. No. KPOD.07.07-IW.07-0250/24). This project had previously been recommended for funding under the Call for Proposals for Entrepreneurs to Conduct Research in the Area of Drug Safety, Innovative Therapies, and Medicines of the Future (2024/ABM/05/KPO), as reported by the Issuer in Current Report No. 3/2025 dated February 7, 2025.

The decision to withdraw from signing the agreement results from a strategic shift in the scope of the Company’s translational research, which will now focus on the treatment of tumors that may benefit from the newly identified blood-brain barrier–penetrating properties of RVU305 — such as gliomas and cancers with a high propensity to metastasize to the brain.

 

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

 

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Kamil Sitarz – Member of the Management Board